Determinants of Treatment Response in Painful Diabetic Peripheral Neuropathy. A Combined Deep Sensory Phenotyping and Multi-modal Brain Magnetic Resonance Imaging Study.
posted on 2020-05-29, 21:15authored byAda AdminAda Admin, Iain David Wilkinson, Kevin Teh, Francesa Heiberg-Gibbons, Mohammad Awadh, Alan Kelsall, Shillo Pallai, Gordon Sloan, Solomon Tesfaye, Dinesh Selvarajah
Painful diabetic polyneuropathy (DPN) is difficult to manage as
treatment response is often varied. The primary aim of this study was to examine
differences in pain phenotypes between responders and non-responders to
intravenous lidocaine treatment using quantitative sensory testing. The secondary
aim was to explore differences in brain structure and functional connectivity with
treatment response. Forty-five consecutive patients who received intravenous
lidocaine treatment for painful DPN were screened. Twenty-nine patients who met
the eligibility criteria (responders n=14 and non-responders n=15) and 26 healthy
controls underwent detailed sensory profiling. Subjects also underwent multimodal
brain magnetic resonance (MR) imaging. Greater proportion of patients with the
irritable (IR) nociceptor phenotype were responders to intravenous lidocaine
treatment compared to non-responders . The odd-ratio of responding to
intravenous lidocaine was 8.67 times greater (95%CI 1.4:53.8) for the IR
nociceptor phenotype. Responders to intravenous lidocaine also had
significantly greater mean S1 cortical volume and functional connectivity
between the insula cortex and the corticolimbic circuitry. This study provides preliminary
evidence for a mechanism-based approach for individualising therapy in patients
with painful DPN.
Funding
This study was supported by the European Foundation for the Study of Diabetes